This present study was designed to follow up 82 patients among 115 MDS patients registered in study ODK-0801 for 5 years, to analyze the relationship between the WT1 mRNA expression level and prognosis.
OBJECTIVE:
This study aimed to investigate the clinical utility of WT1 mRNA expression levels.
METHODS:
After study ODK-0801, we investigated the conditions of the same patients once a year, including any clinical and laboratory findings supporting the diagnosis, and treatment among the living patients.
RESULTS:
When we assessed the survival time of 82 MDS patients by WT1 mRNA expression level, there were significant differences between the< 500 and ≥ 104 copies/μ g RNA groups and between the 500-104 and ≥ 104 copies/μ g RNA groups for BM levels (p < 0.01). Examination of the time of freedom from acute myeloid eukemia(AML) transformation indicated that a high WT1 mRNA expression level(> 104 copies/μ g RNA) was a strong prognostic factor for a short time to AML transformation.
CONCLUSION:
The results indicate that the tumorigenesis of MDS is likely to originate at the stem cell level, suggesting that the WT1 mRNA level measurement in the BM is an effective prognostic marker in patients with MDS.
TamakiH., OgawaH., OhyashikiK., OhyashikiJ.H., IwamaH., InoueK., SomaT., OkaY., TatekawaT., OjiY., TsuboiA., KimE.H., KawakamiM., FuchigamiK., TominagaM., ToyamaK., AozasaK., KishimotoT. and SugiyamaH., The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes, Leukemia13 (1999), 393-9.
2.
CilloniD., GottardiE., MessaF., FavaM., ScaravaglioP., BertiniM., GirottoM., MarinoneC., FerreroD., GallaminiA., LevisA. and SaglioG., Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System score in patients with myelodysplastic syndromes, J Clin Oncol21 (2003), 1988-95.
3.
PatmasiriwatP., FraizerG., KantarjianH. and SaundersG.F., WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia, Leukemia13 (1999), 891-900.
4.
BaderP., NiemeyerC., WeberG., ColivaT., RossiV., KreyenbergH., GereckeA. and BiondiA., WT1 gene expression: Useful marker for minimal residual diseases in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia, Eur J Haematol73 (2004), 25-8.
5.
TamuraK., KanazuwaT., SuzukiM., KoitabashiM., OgawaC. and MorikawaA., Successful rapid discontinuation of immunosuppressive therapy at molecular relapse after allogeneic bone marrow trasplantation in pediatric patients with myelodysplastic syndrome, Am J Hematol81 (2006), 139-41.
6.
IwasakiT., SugisakiC., NagataK., TakagiK., TakagiA., KojimaT., ItoM., NakamuraS., NaoeT. and MurateT., Wilms' tumor 1 message and protein expression in bone marrow failure syndrome and acute leukemia, Pathol Int57 (2007), 645-51.
7.
TamuraH., DanK., YokoseN., IwakiriR., OhtaM., SakamakiH., TohyamaK., KondoA., HyodoH., NakamuraK., YamashitaT., ElisseevaO.A., OkaY., OjiY., SugiyamaH. and OgataK., Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes, Leuk Res34 (2010), 986-90.
8.
GreenbergP., CoxC., LeBeauM.M., FenauxP., MorelP., SanzG., SanzM., VallespiT., HamblinT., OscierD., OhyashikiK., ToyamaK., AulC., MuftiG. and BennettJ., International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood89 (1997), 2079-88.
9.
MalcovatiL., GermingU., KuendgenA., Della PortaM.G., PascuttoC., InvernizziR., GiagounidisA., HildebrandtB., BernasconiP., KnippS., StruppC., LazzarinoM., AulC., and CazzolaM., Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes, J Clin Oncol25 (2007), 3503-10.
10.
UedaY., MizutaniC., NannyaY., KurokawaM., KobayashiS., TakeuchiJ., TamuraH., OgataK., DanK., ShibayamaH., KanakuraY., NiimiK., SasakiK., WatanabeM., EmiN., TeramuraM., MotojiT., KidoM., UsukiK., TakadaS., SakuraT., ItoY., OhyashikiK., OgawaH., SuzukiT., OzawaK., ImaiK., KasaiM., HataT., MiyazakiY., MoritaY., KanamaruA., MatsudaA., TohyamaK., KogaD., TamakiH., MitaniK., NaoeT., SugiyamaH. and TakakuF., Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes, Leuk Lymphoma54 (2013), 1450-8.
11.
MiyawakiS., HatsumiN., TamakiT., NaoeT., OzawaK., KitamuraK., KarasunoT., MitaniK., KoderaY., YamagamiT. and KogaD., Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia, Leuk Lymphoma51 (2010), 1855-61.
12.
GreenbergP.L., TuechlerH., SchanzJ., SanzG., Garcia-ManeroG., SoleF., BennettJ.M., BowenD., FenauxP., DreyfusF., KantarjianH., KuendgenA., LevisA., MalcovatiL., CazzolaM., CermakJ., FonatschC., Le BeauM.M., SlovakM.L., KriegerO., LuebbertM., MaciejewskiJ., MagalhaesSilvia M.M., MiyazakiY., PfeilstockerM., SekeresM., SperrW.R., StauderR., TauroS., ValentP., VallespiT., Van de LoosdrechtA.A., GermingU. and HaaseD., Revised International Prognostic Scoring System for myelodysplastic syndromes, Blood120 (2012), 2454-65.
13.
CutlerC.S., LeeS.J., GreenbergP., DeegH.J., PerezW.S., AnasettiC., BolwellB.J., CairoM.S., GaleR.P., KleinJ.P., LazarusH.M., LiesveldJ.L., McCarthyP.L., MiloneG.A., RizzoJ.D., SchultzK.R., TriggM.E., KeatingA., WeisdorfD., AntinJ.H. and HorowitzM.M., A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome, Blood104 (2004), 579-85.
14.
de WitteT., BrandR., van BiezenA., MuftiG., RuutuT., FinkeJ., von dem BorneP., VitekA., DelforgeM., AlessandrinoP., HarlahakisN., RussellN., MartinoR., VerdonckL., KrogerN. and NiederwieserD., Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: Delay of the transplant is associated with inferior survival, Br J Haematol146 (2009), 627-36.
15.
OmmenH.B., NyvoldC.G., BraendstrupK., AndersenB.L., OmmenI.B., HasleH., HoklandP. and OstergaardM., Relapse prediction in acute myeloid leukemia patients in complete remission using WT1 as a molecular marker: Development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals, Br J Haematol141 (2008), 782-91.
16.
JSHCT, The Japan Society for Hematopoietic Cell Transplantation monograph, 19 (2009), 8.
